These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33484626)

  • 1. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
    Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
    Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
    Dittmann J; Haydn T; Metzger P; Ward GA; Boerries M; Vogler M; Fulda S
    Cell Death Differ; 2020 Jun; 27(6):1878-1895. PubMed ID: 31831875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
    Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
    Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
    Ye W; Gunti S; Allen CT; Hong Y; Clavijo PE; Van Waes C; Schmitt NC
    Oncoimmunology; 2020; 9(1):1710398. PubMed ID: 32002309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoprotective effects of IAPs revealed by a small molecule antagonist.
    Galbán S; Hwang C; Rumble JM; Oetjen KA; Wright CW; Boudreault A; Durkin J; Gillard JW; Jaquith JB; Morris SJ; Duckett CS
    Biochem J; 2009 Feb; 417(3):765-71. PubMed ID: 18851715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
    Foster FM; Owens TW; Tanianis-Hughes J; Clarke RB; Brennan K; Bundred NJ; Streuli CH
    Breast Cancer Res; 2009; 11(3):R41. PubMed ID: 19563669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia regulates TRAIL sensitivity of colorectal cancer cells through mitochondrial autophagy.
    Knoll G; Bittner S; Kurz M; Jantsch J; Ehrenschwender M
    Oncotarget; 2016 Jul; 7(27):41488-41504. PubMed ID: 27166192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
    Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
    Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
    Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
    Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
    Lee EW; Seong D; Seo J; Jeong M; Lee HK; Song J
    Cell Death Differ; 2015 Sep; 22(9):1463-76. PubMed ID: 25613375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
    Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
    BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.
    Derakhshan A; Chen Z; Van Waes C
    Clin Cancer Res; 2017 Mar; 23(6):1379-1387. PubMed ID: 28039268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
    Wang L; Hu C; Zhao Y; Hu X
    Biochem Biophys Res Commun; 2022 Apr; 602():8-14. PubMed ID: 35247703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling.
    Pilling AB; Hwang O; Boudreault A; Laurent A; Hwang C
    Prostate; 2017 Jun; 77(8):866-877. PubMed ID: 28240376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.